Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.

Subjects

Subjects :

Enzyme Inhibitors administration & dosage
Enzyme Inhibitors adverse effects
Gaucher Disease diagnosis
Humans
Pyrrolidines administration & dosage
Pyrrolidines adverse effects
Treatment Outcome
Enzyme Inhibitors therapeutic use
Gaucher Disease drug therapy
Pyrrolidines therapeutic use

Details

Language :

English

ISSN :

1096-0961

Volume :

77

Database :

MEDLINE

Journal :

Blood cells, molecules & diseases

Publication Type :

Editorial & Opinion

Accession number :

31029022

Full Text :

https://doi.org/10.1016/j.bcmd.2019.04.003